Ikarian Capital, LLC Gossamer Bio, Inc. Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.74 - $12.87 $1.05 Million - $7.78 Million	-604,307 Reduced 99.0%	6,100 $13,000
Q3 2022 Nov 14, 2022	SELL	$7.21 - $14.88 $2.81 Million - $5.8 Million	-389,980 Reduced 38.98%	610,407 $7.31 Million
Q2 2022 Aug 12, 2022	BUY	$5.97 - $9.97 $1.34 Million - $2.24 Million	225,072 Added 29.03%	1,000,387 $8.37 Million
Q1 2022 May 13, 2022	SELL	$8.44 - $12.49 $3.31 Million - $4.89 Million	-391,618 Reduced 33.56%	775,315 $6.73 Million
Q4 2021 Feb 14, 2022	SELL	$10.12 - $14.07 $1.87 Million - $2.6 Million	-185,000 Reduced 13.68%	1,166,933 $13.2 Million
Q3 2021 Nov 15, 2021	BUY	$7.25 - $13.23 $2.2 Million - $4.02 Million	303,550 Added 28.95%	1,351,933 $17 Million
Q4 2020 Feb 12, 2021	BUY	$8.3 - $13.59 $3.87 Million - $6.33 Million	465,889 Added 79.98%	1,048,383 $10.1 Million
Q3 2020 Nov 16, 2020	SELL	$11.3 - $14.75 $1.37 Million - $1.79 Million	-121,505 Reduced 17.26%	582,494 $7.23 Million
Q2 2020 Aug 14, 2020	BUY	$9.52 - $15.98 $6.7 Million - $11.2 Million	703,999 New	703,999 $9.15 Million

108

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $81.7M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.